SEC Form 15-12G filed by Sio Gene Therapies Inc.
$SIOX
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number: 001-37418 | |||||
Sio Gene Therapies Inc. | ||
(Exact name of registrant as specified in its charter) | ||
1501 Broadway, 12th Floor New York, NY 10036 (646) 677-6770 | ||
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices) | ||
Common Stock, $0.00001 par value | ||
(Title of each class of securities covered by this Form) | ||
None | ||
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains) | ||
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) | ☒ | |||||||
Rule 12g-4(a)(2) | ☐ | |||||||
Rule 12h-3(b)(1)(i) | ☒ | |||||||
Rule 12h-3(b)(1)(ii) | ☐ | |||||||
Rule 15d-6 | ☐ | |||||||
Rule 15d-22(b) | ☐ | |||||||
Approximate number of holders of record as of the certification or notice date: 4.
Pursuant to the requirements of the Securities Exchange Act of 1934, Sio Gene Therapies Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
SIO GENE THERAPIES INC. | |||||||||||||||||
Dated: | April 25, 2023 | ||||||||||||||||
By: | /s/ David Nassif | ||||||||||||||||
Name: | David Nassif | ||||||||||||||||
Title: | Chief Executive Officer; Chief Financial Officer; Chief Accounting Officer; and General Counsel | ||||||||||||||||